The state of pneumococci asymptomatic carrier in children and its relation to the invasive disease. what has changed after the conjugated vaccine introduction?;Estado de portador de neumococo en niños y su relación con la enfermedad invasiva. ¿qué ha cambiado tras la introducción de la vacuna conjugada?

Pediatria de Atencion Primaria

Volumn 12, Issue 47, 2010, Pages 457-482

  Vera, C García ^a  

^a Vocalía de Comunicación de la AEPap   (Spain)

Author keywords

Colonization; Invasive pneumo coccal disease; Nasopharynx; Pneumococcal conjugated vaccine; Streptococcus pneumoniae

Indexed keywords

EID: 78649471705     PISSN: 11397632     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Musher DM. Streptococcus pneumoniae. En: Mandell GL, Bennett JE, Dolin R (eds.). Enfermedades Infecciosas. Principios y práctica. Buenos Aires: Editorial Médica Panamericana; 2002. p. 2582-2604
2. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144-154.
3. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization: WHO position paper. Wkly Epidemiol Rec. 2007; 82:93-104.
4. Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet. 2001;357:950-952.
5. Jefferson T, Ferroni E, Curtale F, Rossi PG, Borgia P. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect Dis. 2006; 6:405-410.
6. Fedson DS, Scott JAG. The burden of pneu-mococcal disease among adults in developed and developing countries: what is and is not known. Vaccine. 1999;17(suppl. 1):S11-18.
7. Centers for Disease Control and Prevention. Invasive Pneumococcal Disease in Young Children Before Licensure of 13-Valent Pneumococcal Conjugate Vaccine-United States, 2007. MMWR. 2010;59:253-257.
8. De Carvalho Gomes H, Muscat M, Monnet DL, Giesecke J, Lopalco PL. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill. 2009;14(12). pii: 19159.
9. Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L, Hanquet G et al. Temporal trends of invasive Streptococcus pneumoniae se-rotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009; 47:1012-1020.
10. Sánchez-Tatay D, Arroyo LA, Tarragó D, Li-rola MJ, Porras A, Fenoll A et al. Antibiotic susceptibility and molecular epidemiology of nasopharyn-geal pneumococci from Spanish children. Clin Microbiol Infect. 2008;14:797-801.
11. Calbo E, Díaz A, Cañadell E, Fábrega J, Uriz S, Xercavins M et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect. 2006;12:867-872.
12. García-Vera C, Ruiz Andrés MA, Arana Na-varro T, Moneo Hernández I, Castillo Laita JA, Ma-cipe Costa R. Serotipos de neumococo en la nasofaringe de niños preescolares sanos tras la va-cunación antineumocócica conjugada heptavalen-te. Med Clin (Barc). 2010 (en prensa).
13. O'Brien KL, Nohynek H; World Health Organization Pneumococcal Vaccine Trials Carriage Working Group. Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pe-diatr Infect Dis J. 2003;22:e1-11.
14. San José González MA, Méndez Fernández P. Vacuna conjugada neumocócica heptavalente: ¿luces y sombras? Rev Pediatr Aten Primaria. 2008;10:467-488.
15. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J et al. Reduction of nasop-haryngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis. 2002;185:927-936.
16. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R. Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J. 2006;25: 602-607.
17. Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumo-niae in children. J Infect Dis. 2004;190:1203-1211.
18. Tuomanen EI. The biology of pneumococcal infection. Pediatr Res. 1997;42:253-258.
19. Ghaffar F, Muniz LS, Katz K, et al. Effects of large dosages of amoxicillin/clavulanate or azith-romycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonp-neumococcal alphahemolytic streptococci, and Staphylococcus aureus in children with acute otitis media. Clin Infect Dis. 2002;34:1301-1309.
20. Watson DA, Musher DM. A brief history of the pneumococcus in biomedical research. Semin Respir Infect. 1999;14:198-208.
21. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis. 2002;35:547-555.
22. Fenoll A. Tendencias temporales de los seroti-pos neumocócicos en España: 1979-2008. En: Nue-vos Restos y Lecciones Aprendidas. II Reunión de Expertos en Vacunación Antineumocócica Conjuga-da. Abril 2009. Madrid: Wyeth Vaccines; 2009. p. 3.
23. Fenoll A, Jiménez MJ, Vicioso MD. Trends of the ten most prevalent pneumococal serotype among invasive isolates from children in the last 12 years in Spain. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Disea-sesWSPID. Buenos Aires, Argentina, 18-22 November 2009 (Abstract 262).
24. Nurkka A, Ahman H, Korkeila M, Jantti V, Kayhty H, Eskola J. Serum and salivary anti-capsu-lar antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20:25-33.
25. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA et al. Invasive pneumococcal disease caused by nonvaccine se-rotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784-1792.
26. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics. 2005;116:e408-413.
27. Kellner JD, Scheifele D, Vanderkooi OG, Macdonald J, Church DL, Tyrrell GJ. Effects of routine infant vaccination with the 7-valent pneumo-coccal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J. 2008;27:526-532.
28. Laval CB, de Andrade AL, Pimenta FC, de Andrade JG, de Oliveira RM, Silva SA et al. Seroty-pes of carriage and invasive isolates of Streptococcus pneumoniae in Brazilian children in the era of pneumococcal vaccines. Clin Microbiol Infect. 2006;12:50-55.
29. Sandgren A, Sjostrom K, Olsson-Liljequist B, Christensson B, Samuelsson A, Kronvall G et al. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumo-niae. J Infect Dis. 2004;189:785-796.
30. Sjöström K, Spindler C, Ortqvist A, Kalin M, Sandgren A, Kuhlmann-Berezon S et al. Clonal and capsular type decides whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis. 2005;42:451-9.
31. Hausdorff WP, Feikin DR, Klugman KP. Epi-demiological differences among pneumococcal se-rotypes. Lancet Infect Dis. 2005;5:83-93.
32. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30:100-121.
33. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Eng J Med. 2000;343: 1917-1924.
34. Richter SS, Heilmann KP, Coffman SL, Huynh HK, Brueggemann AB, Pfaller MA et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis. 2002;34:330-339.
35. Barnes DM, Whittier S, Gilligan PH, Soares S, Tomasz A, Henderson FW. Transmission of multi-drug-resistant serotype 23F Streptococcus pneu-moniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo. J Infect Dis. 1995;171:890-896.
36. Porat N, Arguedas A, Spratt BG, Trefler R, Brilla E, Loaiza C, Godoy D et al. Emergence of pe-nicillin-nonsusceptible Streptococcus pneumoniae clones expressing serotypes not present in the an-tipneumococcal conjugate vaccine. J Infect Dis. 2004;190:2154-2161.
37. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis. 2008;8:785-795.
38. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococ-cal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244-256.
39. Isaacman DJ, McIntosh D, Reinert RR. Burden of invasive pneumococcal disease and seroty-pe distribution hmong Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:e197-209.
40. Mera R, Miller LA, Fritsche TR, Jones RN. Se-rotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist. 2008;14:101-107.
41. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pe-diatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J. 2007;26:123-128.
42. Finkelstein JA, Huang SS, Daniel J, Rifas-Shi-man SL, Kleinman K, Goldmann D et al. Antibiotic-resistant Streptococcus pneumoniae in the hepta-valent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample. Pediatrics. 2003;112:862-869.
43. Frazão N, Brito-Avô A, Simas C, Saldanha J, Mato R, Nunes S et al. Effect of the seven-va-lent conjugate pneumococcal vaccine on carriage and drug resistance of Streptococcus pneu-moniae in healthy children attending day-care centers in Lisbon. Pediatr Infect Dis J. 2005;24: 243-252.
44. Liñares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect. 2010;16: 402-410.
45. Ghaffar F, Barton T, Lozano J, Muniz LS, Hicks P, Gan V et al. Effect of the 7-valent pneu-mococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis. 2004;39: 930-938.
46. Park SY, Moore MR, Bruden DL, Hyde TB, Reasonover AL, Harker-Jones M et al. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatr Infect Dis J. 2008;27: 335-340.
47. Centers for Disease Control and Prevention (CDC). Pneumonia hospitalizations among young children before and after introduction of pneumo-coccal conjugate vaccine, United States, 1997-2006. MMWR Morb Mortal Wkly Rep. 2009;58: 1-4.
48. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369: 1179-1186.
49. Reingold A, Hadler J, Farley MM, Harrison L, Lynfield R, Lexau C et al. Invasive Pneumococcal Disease in Children 5 Years After Conjugate Vaccine Intrduction. Eigth States 1998-2005.
50. MMWR.Morbidity and Mortality Weekly Report. 2008;57: 144-147.
51. Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analy-sis. Pediatrics. 2009;123:e1103-1110.
52. The UK Health Protection Agency. Current Epidemiology of Invasive Pneumococcal Disease (IPD) [Consultado el 31 de Julio de 2010]. Dispo-nible en www.hpa.org.uk/HPA/Topics/InfectiousDiseases/InfectionsAZ/1220341771909/.
53. Lepoutre A, Varon E, Georges S, Gutmann L, Lévy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill. 2008;13 (35). pii: 18962.
54. Rückinger S, Van der Linden M, Reinert RR, Von Kries R, Burckhardt F, Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococ-cal conjugate vaccine in Germany. Vaccine. 2009; 27:4136-4141.
55. Durando P, Crovari P, Ansaldi F, Sticchi L, Sticchi C, Turello V et al; Collaborative Group for Pneumococcal Vaccination in Ligu-ria. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine. 2009;27:3459-3462.
56. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A et al; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococ-cal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455-1463.
57. Picazo JJ. Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines. Clin Mi-crobiol Infect. 2009;15(Suppl. 3):4-6.
58. Mera R, Miller LA, Fritsche TR, Jones RN. Se-rotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist. 2008;14:101-107.
59. Moore MR, Whitney CG. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? Clin Infect Dis. 2008;46:183-185.
60. Barricarte A, Gil-Setas A, Torroba L, Castilla J, Petit A, Polo I et al. Invasive pneumococcal disease in children younger than 5 years in Navarra, Spain (2000-2005). Impact of the conjugate vaccine. Med Clin (Barc). 2007;129:41-45.
61. Aristegui J, Bernaola E, Pocheville I, García C, Arranz L, Durán G et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2007;26: 303-310.
62. ®). Diferencias en su efectividad en distintas poblaciones. An Sist Sanit Navar. 2008;31:171-192.
63. Muñoz-Almagro C, Jordan I, Gene A, Lato-rre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvacci-ne serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174-182.
64. Artiles F, Horcajada I, Cañas AM, Alamo I, Bordes A, González A. Aspectos epidemioló-gicos de la enfermedad neumocócica invasiva antes y después del uso de la vacuna neumocócica conjugada en Gran Canaria. Enferm Infecc Micro-biol Clin. 2009;27:14-21.
65. Casado-Flores J, Rodrigo C, Arístegui J, Mar-tínón JM, Fenoll A, Mendez C. Decline in pneumo-coccal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. Pe-diatr Infect Dis J. 2008;27:1020-1022.
66. Benito-Fernández J, Raso SM, Pocheville-Gurutzeta I, Sánchez-Etxaniz J, Azcunaga-Santiba-ñez B, Capapé-Zache S. Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain. Pediatr Infect Dis J. 2007;26:667-671.
67. Salleras L, Domínguez A, Ciruela P, Izquier-do C, Borràs E; Grupo de Trabajo del Sistema de Notificación Microbiológica de Cataluña. Impacto de la vacuna neumocócica conjugada heptavalente en una población con valores bajos-intermedios de vacunación. Enferm Infecc Microbiol Clin. 2009; 27:275-277.
68. Informe de la enfermedad neumocócica in-vasiva en la Comunidad de Madrid, año 2007. Bo-letín Epidemiológico de la Comunidad de Madrid. 2008;14:3-33.
69. Boletín Epidemiolóxico de Galicia. A enfermi-dade pneumocócica invasiva en Galicia: 2004-2006. 2007;20:4.
70. Direcció General de Salut Pública. Enferme-dad neumocócica invasiva. Informe 2008 [Consul-tado el 31/07/2010]. Disponible en: www.sp.san.gva.es/DgspPortal/docs/Inf_Enf_Neumo_Inv_2008.pdf.
71. Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, Del Castillo F, Hernandez-Sampela-yo E et al. Serotype distribution of invasive streptococcus pneumoniae among hospitalized pediatric patients in Madrid (may 2007-april 2008) 27th Annual Meeting of the European Society for Paedia-tric Infectious Disease. Brussels, Belgium, June 2009. [P-204].
72. Salleras L, Domínguez A, Ciruela P, Izquier-do C, Navas E, Torner N et al. Changes in seroty-pes causing invasive pneumococcal disease (2005-2007 vs. 1997-1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine. Clin Microbiol Infect. 2009;15:997-1001.
73. Obando I, Muñoz-Almagro C, Arroyo LA, Tarrago D, Sanchez-Tatay D, Moreno-Perez D et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis. 2008; 14:1390-1397.
74. Valera González A. Informe: enfermedad neumocócica invasiva en la Comunidad de Madrid. Descripción de serotipos. Boletín Epidemiológico de la Comunidad de Madrid. 2010;16:43-92.
75. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM et al. Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococ-cal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
76. Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics. 2010;125:26-33.
77. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococ-cal conjugate vaccine on pneumococcal parap-neumonic empyema. Pediatr Infect Dis J. 2006; 25:250-254.
78. Weil-Olivier C, Levy C, Marguet C, Sardet A, de La Rocque F, Lecuyer A et al. Enquête rétros-pective multicentrique sur les pleuropneumopat-hies infectieuses de l'enfant en France. Arch Pe-diatr. 2005;12:823-826.
79. Hsieh YC, Hsueh PR, Lu CY, Lee PI, Lee CY, Huang LM. Clinical manifestations and molecular epidemiology of necrotizing pneumonia and emp-yema caused by Streptococcus pneumoniae in children in Taiwan. Clin Infect Dis. 2004;38:830-835.
80. Eastham KM, Freeman R, Kearns AM, El-tringham G, Clark J, Leeming J et al. Clinical features, aetiology and outcome of empyema in children in the north east of England. Thorax. 2004; 59:522-525.
81. Von Kries R, Hermann M, Hachmeister A, Siedler A, Schmitt HJ, Al-Lahham A et al. Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal di -sease in German children. Pediatr Infect Dis J. 2002;21:1017-1023.
82. Camou T, Palacio R, Di Fabio JL, Hortal M. Invasive pneumococcal diseases in Uruguayan children: comparison between serotype distribution and conjugate vaccine formulations. Vaccine. 2003;2093-2096.
83. Kaltoft MS, Zeuthen N, Konradsen HB. Epidemiology of invasive pneumococcal infections in children aged 0-6 years in Denmark: a 19-year nationwide surveillance study. Acta Paediatr Suppl. 2000;89:3-10.
84. Brandileone MC, De Andrade AL, Di Fabio JL, Guerra ML, Austrian R. Appropriateness of a pneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, with emphasis on meningitis. J Infect Dis. 2003;187: -1206-1212.
85. Hausdorff WP. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur J Pediatr. 2002;161(Suppl.):S135-139.
86. Zissis NP, Syriopoulou V, Kafetzis D, Daikos GL, Tsilimingaki A, Galanakis E et al. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive infections and acute otitis media in children. Eur J Pediatr. 2004;163:364-368.
87. Aguiar SI, Brito MJ, Gonçalo-Marques J, Me-lo-Cristino J, Ramirez M. Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine. 2010;28:5167-5173.
88. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreño RAN, Nohynek H et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD004977.
89. Jansen AGSC, Hak E, Veenhoven RH, Da-moiseaux RAMJ, Schilder AGM, Sanders EAM. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database of Systematic Reviews. 2009; Issue 2. Art. No.: CD001480.
90. Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneu-mococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29:304-309.
91. Millar EV, Watt JP, Bronsdon MA, Dallas J, Reid R, Santosham M et al. Indirect effect of 7-va-lent pneumococcal conjugate vaccine on pneumo-coccal colonization among unvaccinated household members. Clin Infect Dis. 2008;47:989-996.
92. Ardanuy C, Tubau F, Pallares R, Calatayud L, Domínguez MA, Rolo D et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis. 2009;48:57-64.
93. López B, Cima MD, Vázquez F, Fenoll A, Gutiérrez J, Fidalgo C et al. Epidemiological study of Streptococcus pneumoniae carriers in healthy primary-school children. Eur J Clin Microbiol Infect Dis. 1999;18:771-776.
94. Rodrigues F, Nunes S, Sá-Leão R, Gonçalves G, Lemos L, de Lencastre H. Streptococcus pneu-moniae nasopharyngeal carriage in children attending day-care centers in the central region of Portugal, in the era of 7-valent pneumococcal conjugate vaccine. Microb Drug Resist. 2009;15: 269-277.
95. Vestrheim DF, Høiby EA, Aaberge IS, Cau-gant DA. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol. 2010;17:325-334.
96. Dunais B, Bruno P, Carsenti-Dellamonica H, Touboul P, Dellamonica P, Pradier C. Trends in na-sopharyngeal carriage of Streptococcus pneumo-niae among children attending daycare centers in southeastern France from 1999 to 2006. Pediatr Infect Dis J. 2008; 27:1033-1035.
97. Grivea IN, Panagiotou M, Tsantouli AG, Sy-rogiannopoulos GA. Impact of heptavalent pneu-mococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneu-moniae among day-care center attendees in central Greece. Pediatr Infect Dis J. 2008;27:519-525.
98. O'Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, Reid R et al. Effect of pneumococ-cal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis. 2007;196:1211-1220.
99. Atienza Merino G. Evaluación económica de un programa de vacunación frente al neumococo en población pediátrica. Santiago de Compostela: Consellería de Sanidade, Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia, avalia-t; 2010. Serie Avaliación de tecnoloxías. Consultas Técnicas; CT2010/03.
100. Rozenbaum MH, Sanders EA, Van Hoek AJ, Jansen AG, Van der Ende A, Van den Dobbelsteen G et al. Cost effectiveness of pneumococcal vacci nation among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vacci nes. BMJ. 2010;340:c2509.
101. Beall B. Vaccination with the pneumococcal 7-valent conjugate: a successful experiment but the species is adapting. Expert Rev Vaccines. 2007;6:297-300.
102. Hanage WP, Huang SS, Lipsitch M, Bishop CJ, Godoy D, Pelton SI et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis. 2007;195:347-352.
103. Prymula R, Kriz P, Kaliskova E, Pascal T, Po-olman J, Schuerman L. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine. 2009;28:71-78.
104. Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol. 2006;32:139-153.